semaglutide cycle bodybuilding Ozempic bodybuilders push for open access to weight loss drug Exploring the Power of Peptides

McAlister, V

En concreto, la patente de la semaglutida, que es el principio activo detrs de Ozempic y Wegovy, caduca en marzo de 2026 en varios mercados internacionales, haciendo que se abra la puerta a la produccin de los famosos medicamentos genricos que son ms asequibles

Use: In combination with a reduced calorie diet and increased physical activity, to reduce excess body weight and maintain weight reduction long term in patients with obesity, or in patients with overweight in the presence of at least 1 weight-related comorbid condition Usual Adult Dose for Cardiovascular Risk Reduction ORAL: Ozempic Tablets: Initial dose (initiation phase

All exploratory outcomes trended in favor of tirzepatide (Supplementary Table S3)